Neoadjuvant hormonal therapy and external-beam radiotherapy versus external-beam irradiation alone for prostate cancer : AAA quality-of-life analysis;Neoadjuvante Hormontherapie und perkutane Radiotherapie versus alleinige perkutane Radiotherapie beim Prostatakarzinom. Eine Lebensqualitätsanalyse

Strahlentherapie und Onkologie

Volumn 185, Issue 2, 2009, Pages 101-108

  Pinkawa, Michael ^b   Piroth, Marc D ^c   Asadpour, Branka ^c   Gagel, Bernd ^c   Fischedick, Karin ^c   Siluschek, Jaroslav ^c   Kehl, Mareike ^c   Krenkel, Barbara ^c   Eble, Michael J ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c NONE

Author keywords

Hormonal treatment; Prostate neoplasm; Quality of life; Radiotherapy

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; SEXUAL FUNCTION; STRUCTURED QUESTIONNAIRE;

AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; GERMANY; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PREVALENCE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY, CONFORMAL; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 61349186930     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-009-1894-y     Document Type: Article

References (39)

1. M. Bolla L. Collette L. Blank 2002 Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randmised trial Lancet 360 103 8
2. M. Bolla D. Gonzalez P. Warde 1997 Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 295 300
3. J. Crook C. Ludgate S. Malone 2004 Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 60 15 23
4. J. Crook M. McLean C. Catton 2002 Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation Int J Radiat Oncol Biol Phys 52 453 60
5. A.V. D'Amico 2007 Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer J Clin Oncol 25 8 9
6. A.V. D'Amico J.W. Denham J. Crook 2007 Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 25 2420 5
7. A.V. D'Amico J. Manola M. Loffredo 2004 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 292 821 7
8. J.W. Davis D.A. Kuban D.F. Lynch 2001 Quality of life after treatment for localized prostate cancer: differences based on treatment modality J Urol 166 947 52
9. H. Elsayed T. Bolling C. Moustakis 2007 Organ movements and dose exposures in teletherapy of prostate cancer using a rectal balloon Strahlenther Onkol 183 617 24
10. S.J. Feigenberg A.L. Hanlon E.M. Horwitz 2005 Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy Int J Radiat Oncol Biol Phys 62 397 405
11. M. Guckenberger M. Flentje 2007 Intensity-modulated radiotherapy (IMRT) of localized prostate cancer. A review and future perspectives Strahlenther Onkol 183 57 62
12. G.E. Hanks T.F. Pajak A. Porter 2003 Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group protocol 92-02 J Clin Oncol 21 3972 8
13. C. Higano A. Shields N. Wood 2004 Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression Urology 64 1182 6
14. International Commission on Radiation UnitsMeasurements 1993
15. B.A. Jereczek-Fossa F. Cattani C. Garibaldi 2007 Transabdominal ultrasonography, computed tomography and electronic portal imaging for 3-dimensional conformal radiotherapy for prostate cancer Strahlenther Onkol 183 610 6
16. C.A. Lawton M. DeSilvio M. Roach III 2007 An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions Int J Radiat Oncol Biol Phys 69 646 55
17. W. Lilleby E. Dale D.R. Olsen 2003 Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose Acta Oncol 42 10 4
18. G.S. Merrick W.M. Butler K.E. Wallner 2003 Long-term urinary quality of life after permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 56 454 61
19. G.S. Merrick W.M. Butler K.E. Wallner 2004 Influence of hormonal therapy on late rectal function after permanent prostate brachytherapy with or without supplemental external beam radiotherapy Int J Radiat Oncol Biol Phys 58 68 74
20. A.C. Muller U. Ganswindt M. Bamberg 2007 Risk of second malignancies after prostate irradiation? Strahlenther Onkol 183 605 9
21. D. Ososba G. Rodrigues J. Myles 1998 Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 139 44
22. G.D.A. Padula M.J. Zelefsky E.S. Venkatraman 2002 Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 52 439 43
23. M.V. Pilepich K. Winter C.A. Lawton 2005 Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 1285 90
24. M. Pinkawa K. Fischedick B. Asadpour 2008 Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 70 83 9
25. M. Pinkawa K. Fischedick B. Gagel 2006 Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer Urology 68 104 9
26. M. Pinkawa K. Fischedick M.D. Piroth 2006 Health-related quality of life after permanent interstitial brachytherapy for prostate cancer. Correlation with postimplant CT scan parameters Strahlenther Onkol 182 660 5
27. M. Pinkawa K. Fischedick M.D. Piroth 2007 Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy Urology 69 129 33
28. M. Pinkawa B. Gagel M.D. Piroth 2006 Changes of dose delivery distribution within the first month after permanent interstitial brachytherapy for prostate cancer Strahlenther Onkol 182 525 30
29. L. Potters T. Torre P.A. Fearn 2001 Potency after permanent prostate brachytherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 50 1235 42
30. M. Roach III K. Bae J. Speight 2008 Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 J Clin Oncol 26 585 91
31. T.E. Schultheiss W.R. Lee M.A. Hunt 1997 Late GI and GU complications in the treatment of prostate cancer Int J Radiat Oncol Biol Phys 37 3 11
32. M.R. Smith 2004 Changes in fat and lean body during androgen-deprivation therapy for prostate cancer Urology 63 742 5
33. D. Vordermark D. Marold S. Wirth 2007 Patterns of care in the radiotherapy of prostate cancer in Northern Bavaria 1998-2000 Strahlenther Onkol 183 314 20
34. J.T. Wei R.L. Dunn M.S. Litwin 2000 Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer Urology 56 899 905
35. W. Weiss W. Horninger B.C. Forthuber 2007 Single-institution results of primary external-beam radiation for the treatment of T1-T3 prostate cancer Strahlenther Onkol 183 321 6
36. H. Wertz F. Lohr B. Dobler 2007 Dosimetric impact of image-guided translational isocenter correction for 3-D conformal radiotherapy of the prostate Strahlenther Onkol 183 203 10
37. D.R. Wilke C. Parker A. Andonowski 2006 Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists BJU Int 97 963 8
38. M.P. Wirth O.W. Hakenberg M. Froehner 2007 Antiandrogens in the treatment of prostate cancer Eur Urol 51 306 14
39. M.J. Zelefsky A. Harrison 1997 Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy Urology 49 38 45